The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
On May 17, Hims & Hers Health raised its 2026 revenue guidance to $3 billion, exceeding market expectations. The company maintains a long-term target of at least 20% EBITDA margins by 2030. However, it faces short-term margin pressures from branded GLP-1 drugs and international scaling.